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ess: f.chung@imperial.aSummary Background: Neutrophils, in addition to eosinophils, are prominent in
the airways of patients with severe asthma who are usually on long-term oral and
inhaled corticosteroid treatment. We determined whether inhaled or oral
corticosteroid therapy can induce airway neutrophilia.
Methods: We performed two separate placebo-controlled studies in which
patients with mild asthma were treated with either prednisolone (30mg per day
for 7 days; n ¼ 9) or placebo tablets (n ¼ 8), or with either inhaled budesonide
(800 mg twice daily for 4 weeks; n ¼ 6) or inhaled placebo (n ¼ 6). Fiberoptic
bronchoscopy was performed before treatment and at day 7 of oral treatment, and
at day 28 of inhaled therapy. Bronchial sections were immunostained with an
antibody to major basic protein for eosinophils, and with an antibody to neutrophil
elastase for neutrophils. Induced sputum was obtained in the prednisolone study.
Results: Neutrophils in airway submucosa increased after prednisolone from
median 76 to 140/mm2 (P ¼ 0:05); this change was higher than that after placebo
(P ¼ 0:04). Eosinophils decreased from 24 to 9/mm2 (P ¼ 0:03), but this was not
significantly different from placebo. Eosinophils and neutrophils, and levels of IL-8
and myeloperoxidase in induced sputum did not change after prednisolone. There
was no change in neutrophil counts after budesonide, but the reduction in
eosinophils was greater than placebo (P ¼ 0:05). Budesonide improved bronchial
responsiveness, but prednisolone did not.
Conclusion: Corticosteroid therapy by the oral but not inhaled route can induce
neutrophil recruitment into the airways of patients with mild asthma. This could
explain the increase in airway neutrophils observed in severe asthmatics treated
with oral corticosteroids.
r 2004 Elsevier Ltd. All rights reserved.4 Elsevier Ltd. All rights reserved.
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Corticosteroid therapy and airway neutrophils in asthma 201Introduction
The association of airway eosinophilic inflammation
and asthma has been known for more than a 100
years, and the number of eosinophils in bronchial
tissues, in bronchoalveolar lavage and in sputum
correlates with symptoms, bronchial hyperrespon-
siveness and airflow obstruction.1 More recently,
the presence of eosinophils in sputum has been
shown to indicate asthma instability rather than
asthma severity.2 This association of eosinophils
with asthma is further strengthened by the ob-
servation that inhaled corticosteroids, the main-
stay of asthma treatment, suppress eosinophil
infiltration in bronchial tissues, bronchoalveolar
lavage fluid and sputum with improvement in
symptoms, airflow obstruction and bronchial hy-
perresponsiveness.3–5 The significance of neutro-
phil infiltration in asthma is less well documented.
Increased neutrophilic inflammation has been
reported in the airways of patients with sudden-
onset fatal asthma, acute severe asthma and in
nocturnal asthma, and also in patients with severe
asthma.6–11 It is not known how corticosteroid
therapy, which is the mainstay of treatment of
patients with severe asthma, can influence neu-
trophilic trafficking in the airways. Indeed, corti-
costeroids may decrease programmed cell death or
apoptosis of the neutrophil, while increasing
apoptosis in the eosinophil.12 These divergent
effects may lead to a greater persistence of
neutrophils and to a reduction of eosinophils in
the asthmatic airway exposed to corticosteroids.
In order to determine the effect of corticosteroid
therapy on neutrophilic inflammation, we per-
formed fiberoptic bronchoscopic studies in patients
with mild-to-moderate asthma following treatment
with inhaled and with oral corticosteroids, and
measured neutrophil counts in the airways sub-
mucosa. Our studies indicate that corticosteroid
administration by the oral route, but not by the
inhaled route, increases airway neutrophils; how-
ever, inhaled corticosteroids were more effective
in reducing airway eosinophils.Methods
Patients and study design
Patients were enrolled in two double-blind, rando-
mized, placebo-controlled studies, one for an oral
prednisolone study and one for an inhaled budeso-
nide study (Table 1). Both studies were approved by
the Ethics Committee of the Royal BromptonHospital and National Heart and Lung Institute
and all patients gave their informed consent.
Stable, non-smoking patients with asthma, not
treated with inhaled or oral steroids in the previous
3 months were recruited. Patients had a history of
asthma of at least 2 years’ duration and demon-
strated either reversible airways disease or bron-
chial hyperresponsiveness with a PC20p4 mg/l to
methacholine. Airway reversibility was defined by
either an increase in absolute FEV1X12% after
inhaled short-acting b agonist, salbutamol (400 mg),
or a variation of peak flow of X20% over a 2-week
period within the past 12 months. All patients were
atopic, as defined by two or more positive skin prick
tests to common allergens. For the oral predniso-
lone study, patients were randomized to receive
either prednisolone 30mg per day for 7 days or
matched placebo for 7 days. Lung function, induced
sputum and fiberoptic bronchial biopsies were
performed at baseline and repeated at day 7.
For the budesonide study, patients were rando-
mized to receive either inhaled budesonide (800 mg
twice daily) for 4 weeks or inhaled placebo via a
multidose dry powder inhaler (TurbohalerR, Astra
Draco, Sweden). Lung function and fiberoptic
bronchial biopsies were performed at baseline and
repeated on day 28.Fiberoptic bronchoscopy and biopsies
Fiberoptic and bronchial biopsies were carried out
according to conventional guidelines. To minimize
bronchoconstriction, all patients were pretreated
with nebulized salbutamol (2.5mg). Oxygen (3 l/
min) was administered via nasal prongs throughout
the procedure and oxygen saturation was moni-
tored with a digital oximeter. Topical anesthesia of
the upper airways and larynx was achieved using
lidocaine 2%. Biopsies were taken from the seg-
mental and subsegmental carinae in the right lung
and were immediately placed in optimal cutting
temperature (OCT) embedding media, then snap-
frozen in isopentane pre-cooled with liquid nitro-
gen and stored at 70 1C, before sectioning on a
cryostat and immunostaining.Lung function
Baseline spirometric parameters were recorded
using a dry wedge spirometer (Vitalograph, Buck-
ingham, UK). Standardized bronchial provocation
protocol was performed using increasing doubling
concentrations of nebulized isotonic metacholine
solutions. FEV1 was measured after each concen-
tration of metacholine. The challenge was stopped
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Table 1 Patient characteristics.
Oral Prednisolone Inhaled Budesonide
Treated group Control group Treated group Control group
Age (years) 25.0(22.8–26.0) 22.0(21.5–24.0) 26.5(24.0–27.0) 28.5(27.0–30.0)
Gender (M/F) 4/5 7/1 5/1 4/2
FEV1 (l) 3.31(2.42–3.63) 3.52(2.73–4.23) 4.42(3.75–4.76) 3.63(3.37–3.96)
FEV1 (% predicted) 80.0(71.0–88.8) 80.5(69.5–88.5) 98.7(89.5–106.8) 92.8(84.5–101.2)
Data are expressed as median (25–75 percentiles).
L. Tien Nguyen et al.202when a 20% fall in FEV1 was achieved. PC20, the
concentration of metacholine needed to cause a
20% fall in the post-saline FEV1, was calculated by
interpolation of the concentration/FEV1 response.Immunostaining
Consecutive 6 mm frozen bronchial biopsies sections
were immunostained with mouse monoclonal anti-
human antibodies for neutrophil elastase (NE,
Dako, A/S, Denmark) in 1:100 dilution, and major
basic protein (MBP, Monosan, Sanbio AM Uden
Netherlands) in 1:50 dilution. Following 0.3%
hydrogen peroxide in methanol to block endogen-
ous peroxidase for 30min, and 5% horse serum for
20min to block non-specific cross-species reac-
tions, sections were incubated with primary anti-
bodies for 1 h at room temperature. Subsequently,
a biotinylated horse anti-mouse immunoglobulin
followed by a preformed avidin and biotinylated
horseradish peroxidase macromolecular complex
was used as secondary antibody (Vectastain ABC
kit, Vector Laboratories, Burlingame, CA 94010,
USA). Chromogen fast diaminobenzidine was used
to visualize specific immunoreactivity and the
slides were counterstained in 20% hematoxylin
and mounted in dextropropoxyphene.Cell counts
Counting of positive immunoreactive cells was
performed on the whole section, at  400 magni-
fication of a microscope (Zeiss, Germany). Cells
were counted throughout the section including the
epithelium. Results were expressed as total number
of immunoreactive cells per mm2 area. All counts
were made by the same observer without knowl-
edge of the treatment of individual patients. Total
area was measured with KS300 Imaging System 3.0
(Zeiss, Germany).Induced sputum and processing
Sputum induction was performed before and after
treatment period in the oral prednisolone study
only. The method of sputum induction and proces-
sing has been previously described.13 Differential
cell counts were performed on cytospin slides
stained with May–Grunwald–Giemsa. Four hundred
inflammatory cells on each of two slides were
counted by an observer blinded to the clinical
characteristics of the subjects. Sputum superna-
tants were aliquoted in 2ml tubes and stored
at 70 1C.
Sputum supernatant assays
IL-8 assays: IL-8 concentrations were measured
with an amplified sandwich-type enzyme-linked
immunosorbent assay (ELISA). Ninety-six-well mi-
crotiter plates (IL-8 DuoSet Kit, R&D systems,
Abingdon, UK) were coated with mouse anti-human
IL-8 as previously described.14 Duplicate results
were averaged.
Myeloperoxidase (MPO) assays: MPO concentra-
tions were determined with a commercially avail-
able ELISA kit (Calbiochem, San Diego, Ca, USA)
according to the manufacturer’s instructions. The
detection limit of the assay was 1.5 ng/ml. Results
from both assays were adjusted according to a
standard curve determined with 1% dithiotreitol
added in an equivalent concentration to the
samples.
Data analysis
Data are presented as median (25th–75th percen-
tiles). Differences between groups were assessed
with non-parametric Mann–Whitney U-tests, and
differences before and after treatment were also
assessed with non-parametric Wilcoxon test. PC20
data were log10-transformed prior to analysis.
Statistical analyses were performed with Statview
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Corticosteroid therapy and airway neutrophils in asthma 2035.0 software (SAS Institute Inc, SAS Campus Drive,
NC, USA). A p-value of less or equal to 0.05 was
taken as significant.Results
There were no differences in age and baseline FEV1
between the placebo and actively treated groups in
both studies (Table 1). The oral prednisolone
patients had a lower FEV1 than the budesonide
group.
Prednisolone study
Bronchial responsiveness
There were no significant changes in log PC20
following oral prednisolone or placebo treatment.
Changes in log PC20 were not significantly different
before and after treatment in between-group
comparison (Table 2).
Neutrophil elastase immunoreactive cell count
Neutrophil elastase (NE) immunoreactive cell
counts were comparable at baseline in both groups.
NE immunoreactive cells per mm2 increased sig-
nificantly after oral prednisolone from 76 (67–98)
to 140 (103–208) (P ¼ 0:05), but not after placebo
from 69 (58–107) to 64 (45–120) (Fig. 1A). The
change in neutrophil counts was significantly higher
in the prednisolone group compared to the placebo
group (74 (7–123) versus –25 (4–6), P ¼ 0:04;
Fig. 1B).
Major basic protein immunoreactive cell count
Major basic protein (MBP) immunoreactive cell
counts were comparable in both groups at baseline
(24 (15–55) versus 28 (10–47)). MBP immunoreac-
tive cells decreased significantly after oral pre-
dnisolone from 24 (15–55) to 9 (5–24) (P ¼ 0:03),
but not after placebo from 28 (10–47) to 22 (10–35)Table 2 Log10 PC20(mg/ml) during prednisolone and bud
Prednisolone
Prednisolone Control
Pre 0.05(0.57;0.56) 0.14(0.4
Post 0.12(0.70;0.46) 0.43(0.7
Change (post–pre) 0.0(0.5; 0.1) 0.1(0.7;
Results expressed as median (25;75 percentiles). Abbreviation: PC
drop in FEV1.
*Po0.05 compared to post-values.
yP=0.01 compared to control.(Fig. 1C). The change in MBP immunoreactive cells
was not different between groups: Prednisolone:
19 (39–7) versus placebo: –3 (28–11).
Sputum cell counts and sputum IL-8 and MPO
concentrations
At baseline, sputum eosinophils (%) were signi-
ficantly lower in the prednisolone group compared
to placebo group (P ¼ 0:02). There were no
significant changes observed for total, neutro-
phil and eosinophil counts in sputum before and
after treatment in either group. There were no
significant differences in IL-8 and MPO concen-
trations before and after treatment in either
group. There were no correlations between spu-
tum eosinophils and tissue eosinophils, and be-
tween sputum neutrophils and tissue neutrophils
(Table 3).
Budesonide study
Both groups were comparable at baseline for NE
and MBP immunoreactive cell counts.
Bronchial responsiveness
Budesonide caused a significant improvement in log
PC20 (Po0.05), while placebo had no effect.
Change in log PC20 was significantly higher in the
budesonide-treated compared to the placebo-trea-
ted group (P ¼ 0:01) (Table 2).
Neutrophil elastase immunoreactive cell counts
No significant changes were observed in NE immu-
noreactive cells/mm2 after budesonide or placebo
treatment. The changes before and after treatment
were not different in between-group comparison :
78 (23–169) versus 24 (11–38) (Fig. 2A).
Major basic protein immunoreactive cell counts
MBP immunoreactive cells/mm2 were comparable
at baseline. MBP cells/mm2 decreased significantlyesonide studies.
Budesonide
Budesonide Control
5;0.03) 0.17(0.84;0.03)* 0.45(0.06;0.58)
5;0.15) 1.18(0.98;1.49) 0.36(0.00;0.56)
0.2) 1.16(0.97;1.49)y 0.1(1.1;0.8)
20=provocative concentration of methacholine causing a 20%
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Figure 1 Effects of oral prednisolone on total neutrophil
(Panel A), change in neutrophil (Panel B) and eosinophil
(Panel C) counts in bronchial biopsies. Data shown as pre-
and post-treatment with prednisolone or placebo. In
Panel B, change in neutrophil counts represent post-
treatment counts minus pre-treatment counts. Horizon-
tal bars represent median values.
L. Tien Nguyen et al.204after inhaled budesonide from 31 (14–86) to 6 (4–8)
(P ¼ 0:03), but not after placebo from 6 (5–37) to
26 (14–35) (Fig. 2B). The change in MBP immunor-
eactive cell counts was significantly higher in the
budesonide group compared to the placebo group
(16 (79––9) versus 7 (11–19), P ¼ 0:05;
Fig. 2C).Discussion
We determined whether inhaled or oral corticos-
teroid therapy in patients with mild-to-moderate
asthma was associated with an increase in mucosal
neutrophils. We observed an increase in the
number of neutrophils measured in bronchial
biopsies, associated with a decrease in airway
mucosal eosinophils following prednisolone taken
for 7 days, while no changes in mucosal neutro-
phil counts were observed after inhaled budesonide
for 28 days. The inhibition of eosinophilic inflam-
mation by corticosteroid therapy in patients with
asthma is well described,4–5,15 but the effect of
corticosteroids on neutrophilic inflammation has
been less well studied. In accord with our results,
one study found no increase in bronchial tissue
neutrophils, associated with a decrease in tissue
eosinophils, after 8 weeks of inhaled beclometha-
sone therapy in mild-to-moderate asthma pa-
tients.16 There have been no previous reports on
the effect of oral corticosteroid therapy on airway
neutrophils.
We did not include a control non-asthmatic group
in our study, and therefore we were not able to tell
whether the degree of neutrophilia observed was
abnormal. However, we have recently obtained
neutrophil elastase-positive cells in bronchial biop-
sies in a non-asthmatic cohort of nine subjects, and
counted 5–75 (median ¼ 38) neutrophils/mm2 (Nii-
mi A and Chung KF, unpublished observations). The
baseline neutrophil counts seen in this study in the
two groups of mild asthma (prednisolone study; n ¼
17; and budesonide study; n ¼ 12) were all sig-
nificantly higher than that in this normal non-
asthmatic group (P ¼ 0:004 and 0.02, respectively),
indicating that the presence of neutrophilic inflam-
mation in mild asthma. This information indicates
that neutrophilia is not only a feature of severe
asthma, but also of mild asthma. Whether the
submucosal neutrophilia is higher in severe asthma
compared in mild asthma is not known.
We used the results of Hoshino et al.16 to
calculate the number of subjects needed to
demonstrate a significant change in mucosal neu-
trophils after corticosteroid therapy. We calculated
that, on the basis of an increase in neutrophil count
of at least 25 per mm2 mucosal tissue area with a
5% error risk and 95% power, at least 5–6 patients
were needed in each group. Therefore, with the
number of patients actually enrolled in each study,
the statistical analysis was powerful enough to
detect increases in neutrophil counts in both
studies. In addition, we opted to measure neutro-
phil infiltration at day 7 of a 7-day course of oral
prednisolone, and at day 28 of a 28-day course of
ARTICLE IN PRESS
Table 3 Cells counts and supernatant IL-8 and MPO concentrations in induced sputum.
Oral prednisolone Placebo
Before After Before After
Total cell count (105/ml) 2.6 2.6 2.2 1.5
(1.9–5.3) (1.9–3.9) (1.4–2.8) (1.3–2.2)
Neu (%) 21.0 18.3 26.7 15.0
(11.2–43.7) (10.2–41.2) (24.4–40.0) (11.2–25.0)
Eos (%) 5.3* 4.0 10.0* 8.2
(2.9–6.7) (1.9–9.1) (6.8–15.4) (5.2–10.7)
IL-8 (pg/ml) 664.8 681.2 950.0 575.2
(477.1–1089.4) (522.1–1200.8) (213.9–1835.7) (116.2–1403.2)
MPO (ng/ml) 589.6 648.0 636.8 278.4
(281.2–1143.0) (292.8–755.0) (425.2–1539.8) (201.6–705.4)
Abbreviations: Neu=neutrophils, Eos=eosinophils, IL-8=interleukin-8, MPO=myeloperoxidase.
*P=0.02. Results are expressed as median (25–75 percentiles).
Corticosteroid therapy and airway neutrophils in asthma 205inhaled budesonide, when there was significant
suppression of eosinophil mucosal counts in both
studies, as may be expected.
In contrast to the changes in the mucosal biopsy
counts, we did not observe any changes in
eosinophil and neutrophil cell counts in induced
sputum after 1 week of oral prednisolone. A similar
discrepancy between the changes in eosinophils in
bronchial tissue and those recovered in bronchoal-
veolar lavage fluid has been reported following a 4-
week oral prednisolone treatment of asthma
patients;15 thus, no changes in eosinophil counts
in bronchoalveolar lavage fluid were found while in
tissue, there was a significant fall in eosinophil
counts. This may be a reflection of a lesser potent
effect of systemic steroid administration on the
luminal compartment than on airway wall compart-
ment. Sputum eosinophil counts did not reflect
changes in the number of eosinophils within the
airway mucosa.
We found that oral corticosteroids (prednisolone
30mg per day) taken for 7 days did not change
bronchial responsiveness when measured on the 7th
day. It is likely that the effect of corticosteroids in
improving bronchial hyperresponsiveness is a mat-
ter of time and duration of treatment. In a previous
study, after 14 days of prednisone (15mg per day),
no significant improvement in PC20 was observed,
while a 14-day treatment with inhaled beclometha-
sone was found to be more efficacious.17 A 3-week
period of treatment with 12.5mg per day of
prednisone failed to improve bronchial hyperre-
sponsiveness,18 but a 2-week treatment with 20mg
prednisolone per day followed by 4 weeks of 10mg
per day, significantly reduced bronchial hyperre-
sponsiveness.15 On the other hand, we observed a
significant improvement in bronchial responsive-ness following 1 month treatment with budesonide,
consistent with results of previous studies.18,19
The mechanisms underlying the divergent effects
of corticosteroid therapy on neutrophilic and
eosinophilic inflammation are unclear, but one
attractive hypothesis supported by strong in-vitro
evidence is the opposing effect of such therapy on
neutrophil and eosinophil apoptosis or programmed
cell death. Dexamethasone promotes eosinophil
apoptosis while inhibiting neutrophil apoptosis both
in vitro and in vivo.12,20–22 Treatment of asthma
exacerbations with corticosteroids increased the
number of apoptotic eosinophils in sputum.23 Thus,
differences in the regulation of pro- and anti-
apoptotic factors may explain the divergent effects
of corticosteroids on the regulation of apoptosis in
these two different granulocytes.24 Enhanced cor-
ticosteroid-induced neutrophil survival would delay
their tissue removal and the contribution of the
neutrophil to the chronic inflammatory process of
asthma may be enhanced.
Increased numbers of neutrophils in airways
mucosa or recovered from within the lumen has
been described in sudden-onset fatal asthma,6,25 in
intubated patients with status asthmaticus7 and in
patients with severe asthma.10,11,26,27 Airway neu-
trophils are also elevated in nocturnal asthma28 and
during asthma exacerbations.9 Other studies have
reported a negative association of sputum neutro-
phils with FEV1.
29,30 Of interest, we found in this
study that there were a substantial number of
neutrophils in the biopsies of our mild asthmatic
patients, levels that were higher than the corre-
sponding number of eosinophils. This also indicates
that the recruitment of neutrophils to the airways
of patients with mild asthma is not entirely due
to corticosteroid therapy. In the studies where
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Figure 2 Effects of inhaled budesonide on neutrophil
(Panel A), eosinophil (Panel B), and change in eosinophil
(Panel C) counts in bronchial biopsies. Data shown as pre-
and post-treatment with inhaled budesonide or placebo.
Change in eosinophil counts represents post-treatment
counts minus pre-treatment counts. Horizontal bars
represent median values.
L. Tien Nguyen et al.206neutrophils have been associated with several
types of severe asthma, the potential effects of
oral corticosteroid therapy in increasing mucosal
neutrophils cannot be definitely excluded since
most of these patients are usually on maintenance
corticosteroid therapy. Therefore, it is not possibleto determine directly whether the increased
neutrophil count is truly a marker of asthma
severity in these groups.
Whether any functional significance should be
attached to the increased recruitment of neutro-
phils induced by oral corticosteroid therapy is
debatable. Neutrophils have been implicated in
the pathogenesis of bronchial hyperresponsiveness
induced by ozone in animal models.31,32 Levels of
neutrophil myeloperoxidase, an enzyme released
from activated neutrophils, in supernatants from
induced sputum did not change following oral
prednisolone treatment. No changes in sputum
and blood myeloperoxidase concentrations have
been reported after inhaled corticosteroid ther-
apy,26,33 supporting the in vitro finding that the
increased neutrophil survival induced by dexa-
methasone was not associated with cell activation
as assessed by superoxide production or release of
IL-8.20 On the other hand, in severe asthma, there
is evidence of activation of sputum-recovered
neutrophils.10
In summary, our studies indicate that oral but not
inhaled corticosteroids in mild steroid-naive asth-
matics increased airway neutrophil infiltration.
Although, the response of patients with mild
asthma to corticosteroid therapy may not be the
same as in severe asthma, our study suggests that
oral corticosteroid therapy may be a contributory
factor in the increased number of airway neutro-
phils observed in patients with more severe asthma
who are usually on oral corticosteroid therapy.
However, such studies need to be performed in
severe asthmatic patients.Acknowledgements
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